A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

NCT03003039 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Lymphoma

Interventions

BIOLOGICAL: GB241
BIOLOGICAL: Rituximab

Sponsor

Nanjing Yoko Biomedical Co., Ltd.